1311: TERLIPRESSIN IMPROVES OUTCOMES IN PATIENTS WITH HRS AND ALCOHOLIC HEPATITIS: THE CONFIRM STUDY

Introduction: Alcoholic hepatitis (AH) may lead to liver cirrhosis, hepatorenal syndrome (HRS) and subsequently acute-on-chronic liver failure (ACLF). Terlipressin (terli) is FDA-approved to treat HRS, with greater benefit if treatment is initiated when serum creatinine (SCr) is < 5 mg/dL; patients (pts) with ACLF grade 0–2 have a lower risk of respiratory failure. In pts with AH complicated by HRS, terli is associated with a greater rate of HRS reversal versus placebo (pbo). This post hoc analysis of the pbo-controlled CONFIRM study evaluated the efficacy of terli in the subgroup of pts with HRS, ACLF grade 0–2 and SCr < 5 mg/dL, excluding any pts with contraindications or warnings (i.e., ACLF grade 3 or SCr >5 mg/dL) as listed in the US prescribing information (USPI). Methods: The incidence of verified HRS reversal—defined as 2 consecutive SCr values ≤1.5 mg/dL at least 2 hours apart while on treatment and alive without RRT for at least 10 days—and HRS reversal—defined as SCr ≤1.5 mg/dL while on treatment, overall survival up to 90 days, and renal replacement therapy (RRT)-free survival up to Day 90 were assessed. Statistical analyses were performed using a Cochran-Mantel-Haenszel test or a 2-sample log-rank test to compare treatment arms. Results: From the CONFIRM intent-to-treat population (N=300), 117 pts had HRS associated with AH, ACLF grade 0–2, and SCr < 5 mg/dL (terli n=78; pbo n=39). Baseline demographics were comparable across treatment arms. The incidence of verified HRS reversal was significantly higher in pts treated with terli (25/78 [32%]) versus pbo (3/39 [8%], P=0.004), as was the incidence of HRS reversal (terli: 29/78 [37%] vs pbo: 4/39 [10.3%], P=0.002). Overall survival up to 90 days was similar between the terli and pbo arms (log rank P=0.450). The number of pts alive at Day 90 was also similar (37/78 [47%] vs 18/39 [46%]. RRT-free survival was numerically longer in the terli arm compared with pbo (median RRT-free survival: 21 days vs 12 days, log rank P=0.110). Conclusions: In CONFIRM, the largest prospective pbo-controlled study of terli to date, pts with AH and HRS, who met the current USPI criteria (i.e., ACLF grade 0–2 and SCr < 5 mg/dL) had a significantly better response rate than pbo, highlighting the utility of terli in reversing acute kidney injury in pts with AH.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.